CURE’s immunotherapy page features the latest cancer news and updates on immunotherapy Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in immunotherapy.
August 2nd 2022
Subcutaneous (injectable) Tecentriq had similar movement throughout the body, while saving on treatment time compared to intravenous administration of the drug in a group of patients with non-small cell lung cancer.
July 11th 2022
Thanks to the FDA approval of immunotherapy agents, the average survival for patients for stage 4 melanoma has drastically increased over the past 20 years, an expert explained.
May 31st 2022
Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.
April 19th 2022
Patients within the study who developed the rare skin condition were more likely to experience better tumor responses than those who did not develop the side effect.
March 16th 2022
Recent research has demonstrated the ability of immunotherapy combinations to target advanced melanoma.
November 23rd 2021
Immunotherapy side effects are a different than those of chemotherapy and other cancer treatments. Patients should know when to seek emergency care and what to communicate to clinicians.
October 1st 2021
One oncologist highlighted the knowledge base of the immunotherapy and targeted therapy and how they interact with cancer cells.
September 29th 2021
Getting rid of the "blanket statement" and looking deeper into genetics may allow patients with cancer who are older than 60 years to become eligible for immunotherapy, highlighting the importance of further research on the topic.
June 25th 2021
Thanks to ongoing research and clinical trials, it seems that there are always new immunotherapies emerging.
June 16th 2021
BiTE therapy could lead to better ways to target the immune system, while minimizing the chance of resistance.
June 15th 2021
First immunotherapy, intralesional therapy, is making a comeback and producing durable remissions for a subgroup of patients with cancer.
May 21st 2021
The data, according to an expert, show that treatment with Tecentriq could delay disease progression to an advanced stage, as well as the need for more aggressive therapy.
May 14th 2021
New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.
May 9th 2021
Sophisticated analyses can predict which gut microbiome profile may lead to better outcomes to immunotherapy for patients with advanced melanoma.
April 28th 2021
The gut microbiome plays an important role in how patients may respond to cancer treatments, and researchers are learning more about ways to alter it to benefit treatment outcomes.
April 21st 2021
Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.
April 20th 2021
Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.
April 15th 2021
Antibiotics, corticosteroids and proton pump inhibitors could cause negative impacts on survival in patients with non-small cell lung cancer who are receiving treatment with Keytruda.
March 26th 2021
Rozlytrek continues to demonstrate clinical benefit for patients with ROS1 fusion-positive non-small cell lung cancer, which includes patients with central nervous system metastases.
December 3rd 2020
Chimeric antigen receptor (CAR)-T cell therapy is becoming more widely available, with two drugs approved to treat specific blood cancers and more being investigated in clinical trials across cancer types. Here’s what patients need to know if they’re considering treatment with one of these novel immunotherapies.
October 14th 2020
In an interview with CURE®, Dr. Trisha Wise-Draper discusses new findings that show an increased mortality risk for patients with cancer receiving systemic treatments who subsequently contracted COVID-19.
July 28th 2020
The microorganisms inside a patient's gastrointestinal tract may have a role to play in how immunotherapy can treat certain types of cancer.
July 22nd 2020
More than half of the patients (61%) admitted to either the hospital or ICU were discharged and 12% remained in the hospital. Nine patients had died by the time data collection was cut off for this study.
July 6th 2020
Immunotherapy is a wonderful testament to the benefits that arise from our growing understanding of the incredibly intricate human immune system.
July 6th 2020
In the 2020 special issue of CURE on Immunotherapy, we take a look at how the field of immunotherapy continues to grow despite challenges from the COVID-19 pandemic.
July 5th 2020
Cutting-edge medical information and first-person accounts empower patients to evaluate immunotherapy as a treatment option, one organization attests.
June 30th 2020
Across cancer types, a unique immune-stimulating treatment called tumor-infiltrating lymphocyte therapy produces durable remissions that could last for decades.
June 25th 2020
A new tool analyzes patterns of RNA expressed from genes, pinpointing more patients with cancer who can benefit from immunotherapies and targeted drugs.
June 24th 2020
New immunotherapy combinations aim to turbocharge the immune system’s attack against cancer.